Asymptomatic SARS-CoV-2 infection by age: A systematic review and meta-analysis
===============================================================================

* Bing Wang
* Prabha Andraweera
* Salenna Elliott
* Hassen Mohammed
* Zohra Lassi
* Ashley Twigger
* Chloe Borgas
* Shehani Gunasekera
* Shamez Ladhani
* Helen Siobhan Marshall

## Abstract

**Objectives** This systematic review and meta-analysis aimed to estimate the age-specific proportion of asymptomatic SARS-CoV-2 infected persons by year of age.

**Methods** We searched PubMed, Embase, medRxiv and Google Scholar on 10 September 2020 and 1 March 2021. We included studies conducted during January to October 2020, prior to routine vaccination against COVID-19. Since we expected the relationship between the asymptomatic proportion and age to be non-linear, multilevel mixed-effects logistic regression (QR decomposition) with a restricted cubic spline was used to model asymptomatic proportions as a function of age.

**Results** A total of 38 studies were included in the meta-analysis. In total, 6556 out of 14850 cases were reported as asymptomatic. The overall estimate of the proportion of people who became infected with SARS-CoV-2 and remained asymptomatic throughout infection was 44.1% (6556/14850, 95%CI 43.3%-45.0%). The asymptomatic proportion peaked in adolescents (36.2%, 95%CI 26.0%-46.5%) at 13.5 years, gradually decreased by age and was lowest at 90.5 years of age (8.1%, 95%CI 3.4%-12.7%).

**Conclusions** Given the high rates of asymptomatic carriage in adolescents and young adults and their active role in virus transmission in the community, heightened vigilance and public health strategies are needed among these individuals to prevent disease transmission.

Keywords
*   asymptomatic proportion
*   SARS-CoV-2 infection
*   systematic review
*   meta-analysis

## 1. Introduction

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic causing coronavirus disease 2019 (COVID-19) has had a profound impact on public health, our daily life, and economies around the world. Asymptomatic infections have raised concerns about public health policies for managing epidemics because they are a potential source of transmission of the virus and a challenge for controlling the pandemic.1,2 A few systematic reviews have been conducted to determine the contribution of asymptomatic infection to SARS-CoV-2 transmission.1,3-19 Previous researchers attempted to synthesize the best available evidence in different age groups such as children, adults, and elderly.5,7,11,13,16 None, however, have investigated the proportion of asymptomatic SARS-CoV-2 infections throughout the course of infection by age. This review, therefore, aims to 1) identify, assess, and synthesize the evidence on the proportion of people infected with SARS-CoV-2 who were asymptomatic throughout the course of infection, and 2) to estimate asymptomatic proportion by age.

## 2. Methods

### 2.1. Study Design

We conducted this systematic review and meta-analysis based on the statement of the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines20 (Figure 1). The study protocol was registered in the International Prospective Register for Systematic Reviews (PROSPERO, registration number: CRD42020209419).

![Figure 1.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2022/05/05/2022.05.05.22274697/F1.medium.gif)

[Figure 1.](http://medrxiv.org/content/early/2022/05/05/2022.05.05.22274697/F1)

Figure 1. 
The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) flow diagram for article inclusion and exclusion

![Fig 2.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2022/05/05/2022.05.05.22274697/F2.medium.gif)

[Fig 2.](http://medrxiv.org/content/early/2022/05/05/2022.05.05.22274697/F2)

Fig 2. 
Estimates of asymptomatic proportion by age*

*The size of each circle is proportional to the total number of SARS-CoV-2 positive persons reported in each age group in individual studies, with larger circles indicating a larger sample size.

The following study characteristics were considered when estimating the proportion of asymptomatic infections: study period, study population, country, SARS-CoV-2 infection definition, asymptomatic case definition and follow-up period.

### 2.2. Search Strategy

We searched PubMed, Embase, medRxiv and Google Scholar on 10 September 2020 and 1 March 2021 using keywords COVID-19, SARS-CoV-2, 2019-nCoV, coronavirus disease 2019 AND asymptomatic. We only included studied conducted during January to December 2020, prior to routine vaccination against COVID-19 and the emergence of the alpha, delta or omicron variants. Additionally, this review did not identify or include any studies from regions with the beta variant, which was first detected in South Africa in September 2020. Specific search terms suitable to the individual databases were developed. These search terms included combinations of Medical Subject Headings (MeSH)/Emtree and text words contained in the title and abstract.

### 2.3. Selection Criteria

The article selection process occurred in two phases: 1) title and abstract screen: titles and abstracts of articles identified from the electronic databases and from Internet searches were reviewed; 2) full text review: the full text of articles selected at the title and abstract screen were obtained and reviewed for eligibility. The screening process was completed according to a predefined protocol (Supplementary Document 1). We included all studies reporting

*   Proportion of asymptomatic persons among all SARS-CoV-2 infected persons. The numerator includes all SARS-CoV-2 positive persons who were asymptomatic. The denominator includes all SARS-CoV-2 positive persons who tested positive.

*   Prevalence of asymptomatic SARS-CoV-2 positive persons among the defined general population. The numerator includes all SARS-CoV-2 positive persons who were asymptomatic. The denominator is the defined study population who were tested for SARS-CoV-2 (e.g., general population in the local community, healthcare workers, patients on hospital admission, nursing home residents).

*   Asymptomatic infection: a person with confirmed SARS-CoV-2 infection, who has no symptoms at the time of screening (including the first clinical assessment or laboratory test) and had no symptoms throughout the follow-up period.

We excluded 

*   Studies published in languages other than English.

*   Comments, letters, editorials, case reports, consensus reports and reviews.

*   Studies that did not report any age information (e.g., mean or median age) for asymptomatic infections.

*   Studies that clearly stated that the SARS-CoV-2 infected persons were included without any follow up and did not distinguish between asymptomatic and pre-symptomatic infections.

*   Studies that only tested and enrolled asymptomatic persons and/or mild cases.

*   Case studies, case reports and case series with fewer than 20 SARS-CoV-2 infected persons.

*   Case studies, case reports and case series that identified SARS-CoV-2 positive persons through contact tracing where only symptomatic persons were tested.

*   Serology studies that did not check history of symptoms compatible with SARS-CoV-2 infection and enrolled cases confirmed with SARS-CoV-2 infection by use of IgM only.

### 2.4. Data Extraction

We did not assess study quality because the critical appraisal tools which we planned to use are research design-specific, preclude comparison of the quality of different study designs, and cannot reflect heterogeneity of studies reporting proportions with asymptomatic infections. We did, however, consider several methodological factors in the inclusion/exclusion criteria such as the follow-up period and case identification method. Eight authors (BW, PA, SE, HM, ZL, AT, CB, SG) used an online form in Covidence or a Microsoft Excel spreadsheet to extract the following information: study design, setting, study period, study population (sample size, mean or median age, case definition, etc.), country, follow-up duration, and outcomes (number of people sampled/tested, total number of SARS-CoV-2 positive persons, number of asymptomatic SARS-CoV-2 positive persons).

### 2.5. Statistical Analysis

Most studies reporting prevalence of asymptomatic persons among the tested population were cross-sectional community screening studies without regularly follow-up of SARS-CoV-2 positive persons. We excluded screening studies which clearly stated in the Methods or Discussion sections that they did not follow up any cases or could not distinguish between asymptomatic and pre-symptomatic cases. The number of screening studies, which were eligible and included in our review, was small (n=3). Therefore, the percentage of asymptomatic cases among the tested population was not assessed in the meta-analysis. We only assessed percentage of asymptomatic infections among the confirmed population with laboratory confirmed/clinically diagnosed SARS-CoV-2 infections based on history of exposure to SARS-CoV-2 infection and/or suggestive clinical symptoms of pneumonia (Figure 1).

We used a published method to assess the effect of age on proportion of asymptomatic SARS-CoV-2 positive persons.21,22 We anticipated the relationship between the asymptomatic proportion and age in years to be non-linear based on previous reviews.21,22 A multilevel mixed-effects logistic regression (QR decomposition) model with a restricted cubic spline was performed to model the asymptomatic proportion as a function of in years. The restricted cubic spline with five knots placed at the ages of 1.4, 13.5, 33.3, 54.5 and 80.4 years was applied, based on Harrell’s recommended percentiles.23 Studies were nested within region/country as nested random effects. The model allows for multi-levels of nested clusters of random effects on the assumption that observations within the same cluster are correlated. The outcome measure was the number of asymptomatic persons observed in the study population recorded in binomial form, with the number of SARS-CoV-2 positive persons in the study population as the denominator. When the mean age was not available, we estimated the mean age for each age group using the midpoint of the age band. Any studies reporting the proportion of asymptomatic infections using an age band wider than 20 years were excluded from the meta-analysis. Additional efforts were made to contact the first authors for more information where needed. All analyses were performed using Stata 16.1.24

## 3. Results

There were 114 eligible studies. Since a few narrative review and subgroup analyses by age group (e.g., children, adults) have previously been published,5,7,11,13,16 only the results of the meta-analysis are discussed here (Figure 1).

### 3.1. Study Characteristics

A total of 38 studies involving 14850 persons were included in the meta-analysis (Table 1) including 13 paediatric studies (n=2729), 8 studies with adults only (n=1156), and 17 studies with children and adults (n=10965), with an age range of 0 to 100 years. Gender was reported in 37 studies including 8931 (61.2%) males and 5574 (38.4%) females. Of 14850 SARS-CoV-2 positive persons included in the meta-analysis, 5498 were from China, 3643 from India, 1519 from Saudi Arabia, 1255 from Bangladesh, 539 from the US, 417 from Kuwait, 230 from Croatia, 220 from Nepal, 213 from Italy, 203 from Greece, 1113 from the rest of the world. Study settings ranged from community screening to hospital treatment/isolation. In 27 studies, SARS-CoV-2 positive patients were enrolled and followed up in the hospital setting.25-51 Only three community/international traveler/repatriation screening studies52-54 were included as those studies reported follow-up outcomes. In addition, seven disease surveillance studies were included with follow-up outcomes presented in the publication55-59 or correspondence with authors.30,59 In total, 14 studies including a retrospective online survey29,34,36,38,39,43,50,51,55,58-62 which did not clearly state the follow-up period but presented follow-up outcomes, were included in the meta-analysis. The remaining studies followed up patients during the defined follow-up period or during hospital admission. Most SARS-CoV-2 infections were confirmed by RT-PCR. The proportion with asymptomatic infection ranged from 0 to 91.0% with an overall proportion of 44.1%.

View this table:
[Table 1.](http://medrxiv.org/content/early/2022/05/05/2022.05.05.22274697/T1)

Table 1. 
Characteristics of the studies in the meta-analysis

### 3.2. Meta-Analysis

In total, 6556 out of 14850 persons (44.1%, 95%CI 43.3%-45.0%) were reported as asymptomatic throughout the course of infection. The asymptomatic proportion peaked (36.2%, 95%CI: 26.0%-46.5%) at 13.5 years of age, then gradually decreased, levelling out in adults aged 40-50 years, before dropping to 8.1% (95%CI: 3.4%-12.7%) by 90.5 years.

## 4. Discussion

COVID-19 vaccines are highly effective at preventing severe illness, hospitalizations, and death, and have been critical for control the COVID-19 pandemic to restore normal social and economic life.63 The COVID-19 vaccine rollout has been extended to children from 5 years for age in many countries including the US, Australia and Europe. Children and young people have been frequently infected with the Delta or Omicron variants due to high transmissibility and as they remain an under-vaccinated group. Previous reviews and meta-analyses5,7,11,13,16 have demonstrated that children have the highest proportion of asymptomatic infections, which may jeopardize efforts to prevent transmission within a community. However, these reviews only investigated the proportion with asymptomatic infection across wide age ranges such as adults and children. Our review and meta-analysis is the first to calculate more granular estimates of asymptomatic SARS-CoV-2 infection across the age range.

We found a high proportion of asymptomatic infections in children and young people consistent with previous reviews, which reported the highest proportions in children, and lower in adults, especially older adults.5,7,11,13,16 A recent review estimated the pooled percentage of asymptomatic infection to be 41%,11 which is similar to our study result of 44%. Four other reviews reported that at least one third of SARS-CoV-2 infections were asymptomatic.4,12,15,18 Systematic reviews which were conducted during the early stages of the COVID-19 pandemic,5-7,9,10,17,19 however, found that the proportion with asymptomatic infection was much lower than our estimates (13-24%), except for one review13 reporting a pooled percentage of asymptomatic cases of 48%. This review13 included 16 studies in total and four of them64-67 purposefully selected and enrolled asymptomatic SARS-CoV-2 infected persons with 100% of asymptomatic infections. Another review also found that the reported proportion of asymptomatic infections was lower before February 2020 (10%) than after (34%).16 This may be due to changes in testing practices, mitigation measures, and dynamics of different circulating variants over time.

Although we attempted to use best available evidence, high heterogeneities were observed in studies. The ideal study design would be a longitudinal study of population, randomly selected to ensure sample was representative and true asymptomatic infections were captured with a well-defined follow up period. However, testing and isolation policies, study settings, follow-up period, and definition of SARS-CoV-2 infection and asymptomatic cases varied between studies. The study settings ranged from hospital admission to universal screening. COVID-19 disease control policies varied between countries. In some countries such as China and Korea, the majority of infected individuals were hospitalised for treatment or isolation regardless of being symptomatic or asymptomatic. In most other countries, asymptomatic cases have only been required to isolate at home. In studies involving hospital admission, the case notes of hospitalised patients were retrospectively reviewed and proportions of asymptomatic cases reported. Almost two thirds of studies included in the review were studies involving hospitalised patients. Consequently, the proportion of asymptomatic infections may be underestimated if symptomatic patients were more likely to be admitted to hospital. Only a small number of community screening studies were identified in our review, mainly because they were cross-sectional and did not follow up asymptomatic individuals. In the inpatient/outpatient screening studies, patients were admitted to hospital for non-COVID-19 conditions such as obstetric admission, dialysis, and elective surgery, which may not represent the broader population in terms of infection and transmission risk. Additionally, asymptomatic infection rates may be overestimated in COVID-19 testing clinics and outbreak settings such as passengers of cruise ships and airplanes.

The follow up period varied significantly between studies. Each publication was meticulously scrutinized and studies were excluded where asymptomatic infections could not adequately be distinguished from pre-symptomatic infections. In the hospital admission studies, cases were frequently followed up. Duration of follow-up varied from a predefined period of days after test positivity or until two negative PCR tests at least 24 hours apart. Some studies, however, did not specify the duration of follow-up in the publication.

The definition of SARS-CoV-2 and asymptomatic infections used were inconsistent between studies. At the beginning of the pandemic, only respiratory symptoms were considered, and loss of taste or smell was not recognized. Some studies defined SARS-CoV-2 infections using clinical diagnostic criteria including radiology findings without a positive PCR/serology test. Although the majority of patients included in our meta-analysis were diagnosed on PCR testing, a small number of patients were diagnosed based on history of exposure to SARS-CoV-2 infection and/or suggestive clinical symptoms of pneumonia but without a positive PCR test.

Since the onset of the SARS-CoV-2 pandemic, multiple new variants of concern have emerged, including the Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529 and BA.2). In December 2020, the UK was first country to start the COVID-19 vaccine roll-out followed by other countries around the world. The Delta variant first detected in India in October 2020 and became the dominant variant globally until the Omicron variant emerged and spread rapidly across the world in November 2021. The population immunity gained through a combination of infection and vaccination has increased over time. Both variants are transmissible than previously circulating strains and Delta has been shown to cause more severe disease in adults compared to Alpha.68 It is difficult to determine whether Omicron intrinsically causes milder disease than previous variants of concern. The proportion of asymptomatic infections with Omicron is estimated to be much higher,69 which may facilitate more rapid transmission in addition to the variant’s ability to invade both natural and vaccine-induced immunity.70 Our review included studies published before 1 March 2021 and only included from pre-vaccine studies era. The proportion of asymptomatic infections reported in our review does not reflect current epidemiological features of the Delta or Omicron variant. The epidemiology of early variants is different to Omicron.

Mass vaccination against COVID-19 with current available vaccines has been highly effective in preventing severe disease and deaths, and reducing healthcare costs and burden.71-73 One modelling study demonstrated that the benefits of any COVID-19 vaccine, whether highly, moderately, or modestly efficacious by any trial-defined outcome, would depend on how swiftly and broadly it was implemented.74 Given the limited short-term protection provided by current mRNA vaccines against infection nor transmission with the Omicron variant, the priority must be to protect the most vulnerable, especially older adults and those with underlying comorbidities, by ensuring maximum vaccine uptake, boosters as needed and evidence-based mitigations.

Our finding of higher proportion of asymptomatic infections at younger ages suggests that we need to continue to monitor this group closely, especially given that there is currently no vaccine for children under 5 years of age and vaccine uptake is lower in adolescents and children aged 5 years and over compared to adults. An online survey found a higher proportion of parents refused vaccination for their child than the proportion of adults who refused COVID-19 vaccination for themselves.75

Since current mRNA vaccines do not prevent infection or transmission with the Omicron variant, further studies are needed on variant-specific mRNA vaccines and other vaccine platforms. Vaccines with a potential to prevent infection in addition to severe COVID-19 could help reduce community transmission and provide population protection as with the nasal influenza vaccines for children.

## Data Availability

All data produced in the present study are available upon reasonable request to the authors.

## Supplementary Materials

Review Protocol.

## Author Contributions

Conceptualization, S.L. and H.S.M.; literature search and review, B.W., P.A., S.E., H.M, Z.A., C.B., A.T. and S.G.; data extraction, B.W., P.A., S.E., H.M., Z.A., A.T., and C.B.; data analysis, B.W.; writing—original draft preparation, B.W.; writing—review and editing, B.W., P.A., S.E., H.M, Z.A., C.B., A.T., S.G., S.L., and H.S.M.. All authors have read and agreed to the published version of the manuscript.

## Funding

The authors did not receive funding for this project.

## Institutional Review Board Statement

Not applicable.

## Informed Consent Statement

Not applicable.

## Data Availability Statement

All data are accessible on electronic databases (PubMed, GoogleScholar, Scopus, Embase, Medline, Web of Science).

## Conflicts of Interest

H.S.M. is an investigator on vaccine trials sponsored by the GSK group of companies, Pfizer, Sanofi, and Merck. H.S.M.’s, B.W.’s, P.A.’s, and H.M.’s institution receives funding for investigator-led studies from industry, including Pfizer and Sanofi Pasteur; H.S.M., B.W., P.A., and H.M. receive no personal payments from industry. Others have no potential conflicts of interest.

## Acknowledgments

H.S.M. is supported by a National Health and Medical Research Council (NHMRC) Practitioner Fellowship. The authors would like to express their appreciation to Ms. Natalie Dempster for her generous support and assistance with the literature search. Authors would also like to thank Professor Chang-Hoon Kim at Busan Center for infectious Disease Control and Prevention, and Dr Guang Han at Hubei Cancer Hospital for kindly providing additional information.

*   Received May 5, 2022.
*   Revision received May 5, 2022.
*   Accepted May 5, 2022.


*   © 2022, Posted by Cold Spring Harbor Laboratory

The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.

## References

1.  1.Kronbichler A, Kresse D, Yoon S, Lee KH, Effenberger M, Shin JI. Asymptomatic patients as a source of COVID-19 infections: A systematic review and meta-analysis. International journal of infectious diseases. 2020;98:180–6.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=1001016/j.ijid.2020.06.052&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F05%2F05%2F2022.05.05.22274697.atom) 

2.  2.Muller CP. Do asymptomatic carriers of SARS-COV-2 transmit the virus? Lancet Reg Health Eur. 2021 May;4:100082. DOI: 10.1016/j.lanepe.2021.100082
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.lanepe.2021.100082&link_type=DOI) 

3.  3.Al-Sadeq DW, Nasrallah GK. The incidence of the novel coronavirus SARS-CoV-2 among asymptomatic patients: A systematic review. Int J Infect Dis. 2020 Sep;98:372–80. DOI: 10.1016/j.ijid.2020.06.098
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.ijid.2020.06.098&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F05%2F05%2F2022.05.05.22274697.atom) 

4.  4.Alene M, Yismaw L, Assemie MA, Ketema DB, Mengist B, Kassie B, et al. Magnitude of asymptomatic COVID-19 cases throughout the course of infection: A systematic review and meta-analysis. PLoS One. 2021;16(3):e0249090. DOI: 10.1371/journal.pone.0249090
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/journal.pone.0249090&link_type=DOI) 

5.  5.Buitrago-Garcia D, Egli-Gany D, Counotte MJ, Hossmann S, Imeri H, Ipekci AM, et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis. PLoS Med. 2020 Sep;17(9):e1003346. DOI: 10.1371/journal.pmed.1003346
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/journal.pmed.1003346&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32960881&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F05%2F05%2F2022.05.05.22274697.atom) 

6.  6.Byambasuren O, Cardona M, Bell K, Clark J, McLaws M-L, Glasziou P. Estimating the extent of asymptomatic COVID-19 and its potential for community transmission: systematic review and meta-analysis. Official Journal of the Association of Medical Microbiology and Infectious Disease Canada. 2020;5(4):223–34.
    
    

7.  7.Chen X, Huang Z, Wang J, Zhao S, Wong MC-S, Chong KC, et al. Ratio of asymptomatic COVID-19 cases among ascertained SARS-CoV-2 infections in different regions and population groups in 2020: a systematic review and meta-analysis including 130 123 infections from 241 studies. BMJ Open. 2021;11(12):e049752. DOI: 10.1136/bmjopen-2021-049752
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NzoiYm1qb3BlbiI7czo1OiJyZXNpZCI7czoxMzoiMTEvMTIvZTA0OTc1MiI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIyLzA1LzA1LzIwMjIuMDUuMDUuMjIyNzQ2OTcuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

8.  8.Gao Z, Xu Y, Sun C, Wang X, Guo Y, Qiu S, et al. A systematic review of asymptomatic infections with COVID-19. Journal of Microbiology, Immunology and Infection. 2021;54(1):12–6.
    
    

9.  9.He J, Guo Y, Mao R, Zhang J. Proportion of asymptomatic coronavirus disease 2019: A systematic review and meta-analysis. Journal of medical virology. 2021;93(2):820–30.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F05%2F05%2F2022.05.05.22274697.atom) 

10. 10.Hoang A, Chorath K, Moreira A, Evans M, Burmeister-Morton F, Burmeister F, et al. COVID-19 in 7780 pediatric patients: A systematic review. EClinicalMedicine. 2020 Jul;24:100433. DOI: 10.1016/j.eclinm.2020.100433
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.eclinm.2020.100433&link_type=DOI) 

11. 11.Ma Q, Liu J, Liu Q, Kang L, Liu R, Jing W, et al. Global Percentage of Asymptomatic SARS-CoV-2 Infections Among the Tested Population and Individuals With Confirmed COVID-19 Diagnosis: A Systematic Review and Meta-analysis. JAMA network open. 2021;4(12):e2137257–e.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/JAMANETWORKOPEN.2021.37257&link_type=DOI) 

12. 12.Sah P, Fitzpatrick MC, Zimmer CF, Abdollahi E, Juden-Kelly L, Moghadas SM, et al. Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis. Proceedings of the National Academy of Sciences. 2021;118(34):e2109229118. DOI: 10.1073/pnas.2109229118
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NDoicG5hcyI7czo1OiJyZXNpZCI7czoxODoiMTE4LzM0L2UyMTA5MjI5MTE4IjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjIvMDUvMDUvMjAyMi4wNS4wNS4yMjI3NDY5Ny5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

13. 13.Syangtan G, Bista S, Dawadi P, Rayamajhee B, Shrestha LB, Tuladhar R, et al. Asymptomatic SARS-CoV-2 carriers: a systematic review and meta-analysis. Frontiers in public health. 2021;8:1066.
    
    

14. 14.Yanes-Lane M, Winters N, Fregonese F, Bastos M, Perlman-Arrow S, Campbell JR, et al. Proportion of asymptomatic infection among COVID-19 positive persons and their transmission potential: A systematic review and meta-analysis. PLOS ONE. 2020;15(11):e0241536. DOI: 10.1371/journal.pone.0241536
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/journal.pone.0241536&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=33141862&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F05%2F05%2F2022.05.05.22274697.atom) 

15. 15.Oran DP, Topol EJ. The Proportion of SARS-CoV-2 Infections That Are Asymptomatic : A Systematic Review. Ann Intern Med. 2021 May;174(5):655–62. DOI: 10.7326/m20-6976
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.7326/m20-6976&link_type=DOI) 

16. 16.Chen C, Zhu C, Yan D, Liu H, Li D, Zhou Y, et al. The epidemiological and radiographical characteristics of asymptomatic infections with the novel coronavirus (COVID-19): A systematic review and meta-analysis. Int J Infect Dis. 2021 Mar;104:458–64. DOI: 10.1016/j.ijid.2021.01.017
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.ijid.2021.01.017&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F05%2F05%2F2022.05.05.22274697.atom) 

17. 17.Beale S, Hayward A, Shallcross L, Aldridge R, Fragaszy E. A rapid review and meta-analysis of the asymptomatic proportion of PCR-confirmed SARS-CoV-2 infections in community settings [version 1; peer review: 1 approved with reservations]. Wellcome Open Research. 2020;5(266). DOI: 10.12688/wellcomeopenres.16387.1
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.12688/wellcomeopenres.16387.1&link_type=DOI) 

18. 18.Oran DP, Topol EJ. Prevalence of Asymptomatic SARS-CoV-2 Infection. Ann Intern Med. 2021 Feb;174(2):286–7. DOI: 10.7326/L20-1285
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.7326/L20-1285&link_type=DOI) 

19. 19.Cui X, Zhao Z, Zhang T, Guo W, Guo W, Zheng J, et al. A systematic review and meta-analysis of children with coronavirus disease 2019 (COVID-19). J Med Virol. 2021 Feb;93(2):1057–69. DOI: 10.1002/jmv.26398
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/jmv.26398&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32761898&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F05%2F05%2F2022.05.05.22274697.atom) 

20. 20.Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Open Med. 2009;3(3):e123–30.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.2174/1874306400903010123&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=21603045&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F05%2F05%2F2022.05.05.22274697.atom) 

21. 21.Wang B, Santoreneos R, Giles L, Haji Ali Afzali H, Marshall H. Case fatality rates of invasive meningococcal disease by serogroup and age: A systematic review and meta-analysis. Vaccine. 2019 May 9;37(21):2768–82. DOI: 10.1016/j.vaccine.2019.04.020
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.vaccine.2019.04.020&link_type=DOI) 

22. 22.Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis. 2010 Dec;10(12):853–61. DOI: 10.1016/S1473-3099(10)70251-6
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S1473-3099(10)70251-6&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=21075057&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F05%2F05%2F2022.05.05.22274697.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000285530600020&link_type=ISI) 

23. 23.Harrell FE. General aspects of fitting regression models. Regression modeling strategies: Springer; 2015. p. 13–44.
    
    

24. 24.Statistical Software: Release 16.1 (StataCorp, 2019) [Internet]. Available from: [https://www.stata.com](https://www.stata.com).
    
    

25. 25.Alshukry A, Ali H, Ali Y, Al-Taweel T, Abu-Farha M, AbuBaker J, et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) patients in Kuwait. PLoS One. 2020;15(11):e0242768. DOI: 10.1371/journal.pone.0242768
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/journal.pone.0242768&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F05%2F05%2F2022.05.05.22274697.atom) 

26. 26.Bhandari S, Bhargava A, Sharma S, Keshwani P, Sharma R, Banerjee S. Clinical Profile of Covid-19 Infected Patients Admitted in a Tertiary Care Hospital in North India. J Assoc Physicians India. 2020 May;68(5):13–7.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F05%2F05%2F2022.05.05.22274697.atom) 

27. 27.Chaudhary A, Singh UN, Paudel P, Thapa N, Khadka K, Sah PK, et al. Characteristics and outcomes of hospitalized adults with COVID-19 in Nepal: a multicenter, prospective cohort study. medRxiv. 2020:2020.10.03.20206128. DOI: 10.1101/2020.10.03.20206128
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NzoibWVkcnhpdiI7czo1OiJyZXNpZCI7czoyMToiMjAyMC4xMC4wMy4yMDIwNjEyOHYxIjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjIvMDUvMDUvMjAyMi4wNS4wNS4yMjI3NDY5Ny5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

28. 28.Chua GT, Xiong X, Choi EH, Han MS, Chang SH, Jin BL, et al. COVID-19 in children across three Asian cosmopolitan regions. Emerg Microbes Infect. 2020 Dec;9(1):2588–96. DOI: 10.1080/22221751.2020.1846462
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1080/22221751.2020.1846462&link_type=DOI) 

29. 29.Grechukhina O, Greenberg V, Lundsberg LS, Deshmukh U, Cate J, Lipkind HS, et al. Coronavirus disease 2019 pregnancy outcomes in a racially and ethnically diverse population. Am J Obstet Gynecol MFM. 2020 Nov;2(4):100246. DOI: 10.1016/j.ajogmf.2020.100246
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.ajogmf.2020.100246&link_type=DOI) 

30. 30.Khan S, Ali A, Shi H, Siddique R, Shabana, Nabi G, et al. COVID-19: Clinical aspects and therapeutics responses. Saudi Pharm J. 2020;28(8):1004–8. DOI: 10.1016/j.jsps.2020.06.022
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.jsps.2020.06.022&link_type=DOI) 

31. 31.Krajcar N, Stemberger Maric L, Šurina A, Kurecic Filipovic S, Trkulja V, Roglic S, et al. Epidemiological and clinical features of Croatian children and adolescents with a PCR-confirmed coronavirus disease 2019: differences between the first and second epidemic wave. Croat Med J. 2020;61(6):491–500. DOI: 10.3325/cmj.2020.61.491
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.3325/cmj.2020.61.491&link_type=DOI) 

32. 32.Li J, Thoon KC, Chong CY, Maiwald M, Kam KQ, Nadua K, et al. Comparative Analysis of Symptomatic and Asymptomatic SARS-CoV-2 Infection in Children. Ann Acad Med Singap. 2020 Aug;49(8):530–7.
    
    

33. 33.Liu S, Yuan C, Lin J, Gao W, Tian D, Cai X, et al. Association between vaccinations and clinical manifestations in children with COVID-19. Translational Pediatrics. 2021;10(1):17–25.
    
    

34. 34.Liu X, Lv J, Gan L, Zhang Y, Sun F, Meng B, et al. Comparative analysis of clinical characteristics, imaging and laboratory findings of different age groups with COVID-19. Indian J Med Microbiol. 2020 Jan-Mar;38(1):87–93. DOI: 10.4103/ijmm.IJMM\_20\_133
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access\_num=10.4103/ijmm.IJMM_20_133&link_type=DOI) 

35. 35.Mannan A, Mehedi HMH, Chy N, Qayum MO, Akter F, Rob MA, et al. A multi-centre, cross-sectional study on coronavirus disease 2019 in Bangladesh: clinical epidemiology and short-term outcomes in recovered individuals. New Microbes New Infect. 2021 Mar;40:100838. DOI: 10.1016/j.nmni.2021.100838
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.nmni.2021.100838&link_type=DOI) 

36. 36.Marcus N, Frizinsky S, Hagin D, Ovadia A, Hanna S, Farkash M, et al. Minor Clinical Impact of COVID-19 Pandemic on Patients With Primary Immunodeficiency in Israel. Front Immunol. 2020;11:614086. DOI: 10.3389/fimmu.2020.614086
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.3389/fimmu.2020.614086&link_type=DOI) 

37. 37.Martini F, D’Alessio A, Bracchi F, Di Mauro D, Fargnoli A, Motta M, et al. On Cancer, COVID-19, and CT Scans: A Monocentric Retrospective Study. J Clin Med. 2020 Dec 4;9(12). DOI: 10.3390/jcm9123935
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.3390/jcm9123935&link_type=DOI) 

38. 38.Meyts I, Bucciol G, Quinti I, Neven B, Fischer A, Seoane E, et al. Coronavirus disease 2019 in patients with inborn errors of immunity: An international study. J Allergy Clin Immunol. 2021 Feb;147(2):520–31. DOI: 10.1016/j.jaci.2020.09.010
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.jaci.2020.09.010&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32980424&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F05%2F05%2F2022.05.05.22274697.atom) 

39. 39.Panagiotakopoulos L, Myers TR, Gee J, Lipkind HS, Kharbanda EO, Ryan DS, et al. SARS-CoV-2 Infection Among Hospitalized Pregnant Women: Reasons for Admission and Pregnancy Characteristics - Eight U.S. Health Care Centers, March 1-May 30, 2020. MMWR Morb Mortal Wkly Rep. 2020 Sep 23;69(38):1355–9. DOI: 10.15585/mmwr.mm6938e2
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.15585/mmwr.mm6938e2&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F05%2F05%2F2022.05.05.22274697.atom) 

40. 40.Parri N, Lenge M, Cantoni B, Arrighini A, Romanengo M, Urbino A, et al. COVID-19 in 17 Italian Pediatric Emergency Departments. Pediatrics. 2020 Dec;146(6). DOI: 10.1542/peds.2020-1235
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MTA6InBlZGlhdHJpY3MiO3M6NToicmVzaWQiO3M6MTU6IjE0Ni82L2UyMDIwMTIzNSI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIyLzA1LzA1LzIwMjIuMDUuMDUuMjIyNzQ2OTcuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

41. 41.Peng X, Guo Y, Xiao H, Xia W, Zhai A, Zhu B, et al. Overview of chest involvement at computed tomography in children with coronavirus disease 2019 (COVID-19). Pediatr Radiol. 2021;51(2):222–30. DOI: 10.1007/s00247-020-04826-7
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s00247-020-04826-7&link_type=DOI) 

42. 42.Pongpirul WA, Wiboonchutikul S, Charoenpong L, Panitantum N, Vachiraphan A, Uttayamakul S, et al. Clinical course and potential predictive factors for pneumonia of adult patients with Coronavirus Disease 2019 (COVID-19): A retrospective observational analysis of 193 confirmed cases in Thailand. PLoS Negl Trop Dis. 2020 Oct;14(10):e0008806. DOI: 10.1371/journal.pntd.0008806
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/journal.pntd.0008806&link_type=DOI) 

43. 43.Sahu AK, Dhar A, Aggarwal B. Radiographic features of COVID-19 infection at presentation and significance of chest X-ray: Early experience from a super-specialty hospital in India. Indian J Radiol Imaging. 2021 Jan;31(Suppl 1):S128-s33. DOI: 10.4103/ijri.IJRI\_368\_20
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access\_num=10.4103/ijri.IJRI_368_20&link_type=DOI) 

44. 44.Song R, Han B, Song M, Wang L, Conlon CP, Dong T, et al. Clinical and epidemiological features of COVID-19 family clusters in Beijing, China. J Infect. 2020 Aug;81(2):e26–e30. DOI: 10.1016/j.jinf.2020.04.018
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.jinf.2020.04.018&link_type=DOI) 

45. 45.Sun D, Zhu F, Wang C, Wu J, Liu J, Chen X, et al. Children Infected With SARS-CoV-2 From Family Clusters. Front Pediatr. 2020;8:386. DOI: 10.3389/fped.2020.00386
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.3389/fped.2020.00386&link_type=DOI) 

46. 46.Temel H, Gündüz M, Arslan H, Ünal F, Atag E, Cömert M, et al. Evaluation of the clinical features of 81 patients with COVID-19: An unpredictable disease in children. Journal of Pediatric Infectious Diseases. 2021;16(02):047–52.
    
    

47. 47.Wu X, Sun R, Chen J, Xie Y, Zhang S, Wang X. Radiological findings and clinical characteristics of pregnant women with COVID-19 pneumonia. Int J Gynaecol Obstet. 2020 Jul;150(1):58–63. DOI: 10.1002/ijgo.13165
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/ijgo.13165&link_type=DOI) 

48. 48.Xu H, Liu E, Xie J, Smyth RL, Zhou Q, Zhao R, et al. A follow-up study of children infected with SARS-CoV-2 from western China. Ann Transl Med. 2020 May;8(10):623. DOI: 10.21037/atm-20-3192
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.21037/atm-20-3192&link_type=DOI) 

49. 49.Yan X, Han X, Peng D, Fan Y, Fang Z, Long D, et al. Clinical Characteristics and Prognosis of 218 Patients With COVID-19: A Retrospective Study Based on Clinical Classification. Front Med (Lausanne). 2020;7:485. DOI: 10.3389/fmed.2020.00485
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.3389/fmed.2020.00485&link_type=DOI) 

50. 50.Yayla BCC, Aykac K, Ozsurekci Y, Ceyhan M. Characteristics and Management of Children With COVID-19 in a Tertiary Care Hospital in Turkey. Clinical Pediatrics. 2021;60(3):170–7. DOI: 10.1177/0009922820966306
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1177/0009922820966306&link_type=DOI) 

51. 51.Zhang S, Guo M, Wu F, Xiong N, Ma Y, Wang Z, et al. Factors associated with asymptomatic infection in health-care workers with severe acute respiratory syndrome coronavirus 2 infection in Wuhan, China: a multicentre retrospective cohort study. Clin Microbiol Infect. 2020 Dec;26(12):1670–5. DOI: 10.1016/j.cmi.2020.08.038
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.cmi.2020.08.038&link_type=DOI) 

52. 52.Bailie CR, Franklin L, Nicholson S, Mordant F, Alpren C, Stewart T, et al. Symptoms and laboratory manifestations of mild COVID-19 in a repatriated cruise ship cohort. Epidemiol Infect. 2021 Feb 10;149:e44. DOI: 10.1017/S0950268821000315
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1017/S0950268821000315&link_type=DOI) 

53. 53.Lavezzo E, Franchin E, Ciavarella C, Cuomo-Dannenburg G, Barzon L, Del Vecchio C, et al. Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo’. Nature. 2020 Aug;584(7821):425–9. DOI: 10.1038/s41586-020-2488-1
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/s41586-020-2488-1&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32604404&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F05%2F05%2F2022.05.05.22274697.atom) 

54. 54.Ren R, Zhang Y, Li Q, McGoogan JM, Feng Z, Gao GF, et al. Asymptomatic SARS-CoV-2 Infections Among Persons Entering China From April 16 to October 12, 2020. JAMA. 2021;325(5):489–92. DOI: 10.1001/jama.2020.23942
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/jama.2020.23942&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=33528529&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F05%2F05%2F2022.05.05.22274697.atom) 

55. 55.Alsofayan YM, Althunayyan SM, Khan AA, Hakawi AM, Assiri AM. Clinical characteristics of COVID-19 in Saudi Arabia: A national retrospective study. J Infect Public Health. 2020 Jul;13(7):920–5. DOI: 10.1016/j.jiph.2020.05.026
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.jiph.2020.05.026&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32534945&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F05%2F05%2F2022.05.05.22274697.atom) 

56. 56.Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, et al. Epidemiology of COVID-19 Among Children in China. Pediatrics. 2020;145(6). DOI: 10.1542/peds.2020-0702
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MTA6InBlZGlhdHJpY3MiO3M6NToicmVzaWQiO3M6MTU6IjE0NS82L2UyMDIwMDcwMiI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIyLzA1LzA1LzIwMjIuMDUuMDUuMjIyNzQ2OTcuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

57. 57.Hurst JH, Heston SM, Chambers HN, Cunningham HM, Price MJ, Suarez L, et al. Severe Acute Respiratory Syndrome Coronavirus 2 Infections Among Children in the Biospecimens from Respiratory Virus-Exposed Kids (BRAVE Kids) Study. Clin Infect Dis. 2021;73(9):e2875–e82. DOI: 10.1093/cid/ciaa1693
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/cid/ciaa1693&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=33141180&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F05%2F05%2F2022.05.05.22274697.atom) 

58. 58.Maltezou HC, Magaziotou I, Dedoukou X, Eleftheriou E, Raftopoulos V, Michos A, et al. Children and Adolescents With SARS-CoV-2 Infection: Epidemiology, Clinical Course and Viral Loads. Pediatr Infect Dis J. 2020 Dec;39(12):e388–e92. DOI: 10.1097/INF.0000000000002899
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1097/INF.0000000000002899&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F05%2F05%2F2022.05.05.22274697.atom) 

59. 59.Mattar S, Martinez-Bravo C, Rivero R, Contreras H, Faccini-Martínez ÁA, Guzman-Teran C, et al. Epidemiological and viral features of a cohort of SARS-CoV-2 symptomatic and asymptomatic individuals in an area of the Colombian Caribbean. Annals of Clinical Microbiology and Antimicrobials. 2020 2020/12/07;19(1):58. DOI: 10.1186/s12941-020-00397-5
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1186/s12941-020-00397-5&link_type=DOI) 

60. 60.Hasan MJ, Chowdhury SM, Khan MAS, Rahaman M, Fardous J, Adit T, et al. Clinico-epidemiological characteristics of asymptomatic and symptomatic COVID-19-positive patients in Bangladesh. medRxiv. 2020:2020.08.18.20177089. DOI: 10.1101/2020.08.18.20177089
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NzoibWVkcnhpdiI7czo1OiJyZXNpZCI7czoyMToiMjAyMC4wOC4xOC4yMDE3NzA4OXYxIjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjIvMDUvMDUvMjAyMi4wNS4wNS4yMjI3NDY5Ny5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

61. 61.Kumar N, Shahul Hameed SK, Babu GR, Venkataswamy MM, Dinesh P, Kumar Bg P, et al. Descriptive epidemiology of SARS-CoV-2 infection in Karnataka state, South India: Transmission dynamics of symptomatic vs. asymptomatic infections. EClinicalMedicine. 2021 Feb;32:100717. DOI: 10.1016/j.eclinm.2020.100717
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.eclinm.2020.100717&link_type=DOI) 

62. 62.Son H, Lee H, Lee M, Eun Y, Park K, Kim S, et al. Epidemiological characteristics of and containment measures for COVID-19 in Busan, Korea. Epidemiol Health. 2020;42:e2020035. DOI: 10.4178/epih.e2020035
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.4178/epih.e2020035&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F05%2F05%2F2022.05.05.22274697.atom) 

63. 63.Gostin LO, Salmon DA, Larson HJ. Mandating COVID-19 Vaccines. JAMA. 2021 Feb 9;325(6):532–3. DOI: 10.1001/jama.2020.26553
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/jama.2020.26553&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F05%2F05%2F2022.05.05.22274697.atom) 

64. 64.Hu Z, Song C, Xu C, Jin G, Chen Y, Xu X, et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. Sci China Life Sci. 2020 May;63(5):706–11. DOI: 10.1007/s11427-020-1661-4
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s11427-020-1661-4&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32146694&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F05%2F05%2F2022.05.05.22274697.atom) 

65. 65.Meng H, Xiong R, He R, Lin W, Hao B, Zhang L, et al. CT imaging and clinical course of asymptomatic cases with COVID-19 pneumonia at admission in Wuhan, China. J Infect. 2020 Jul;81(1):e33–e9. DOI: 10.1016/j.jinf.2020.04.004
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.jinf.2020.04.004&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32294504&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F05%2F05%2F2022.05.05.22274697.atom) 

66. 66.Pan Y, Yu X, Du X, Li Q, Li X, Qin T, et al. Epidemiological and Clinical Characteristics of 26 Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Carriers. J Infect Dis. 2020 Jun 11;221(12):1940–7. DOI: 10.1093/infdis/jiaa205
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/infdis/jiaa205&link_type=DOI) 

67. 67.Wang Y, Liu Y, Liu L, Wang X, Luo N, Li L. Clinical Outcomes in 55 Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Who Were Asymptomatic at Hospital Admission in Shenzhen, China. J Infect Dis. 2020 May 11;221(11):1770–4. DOI: 10.1093/infdis/jiaa119
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/infdis/jiaa119&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F05%2F05%2F2022.05.05.22274697.atom) 

68. 68.Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, Andrews N, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet. 2022 Apr 2;399(10332):1303–12. DOI: 10.1016/S0140-6736(22)00462-7
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S0140-6736(22)00462-7&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=35305296&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F05%2F05%2F2022.05.05.22274697.atom) 

69. 69.Murray CJL. COVID-19 will continue but the end of the pandemic is near. Lancet. 2022 Jan 29;399(10323):417–9. DOI: 10.1016/S0140-6736(22)00100-3
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S0140-6736(22)00100-3&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=35065006&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F05%2F05%2F2022.05.05.22274697.atom) 

70. 70.Pulliam JRC, van Schalkwyk C, Govender N, von Gottberg A, Cohen C, Groome MJ, et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa. Science. 2022 Mar 15:eabn4947. DOI: 10.1126/science.abn4947
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1126/science.abn4947&link_type=DOI) 

71. 71.Wang WC, Fann JC, Chang RE, Jeng YC, Hsu CY, Chen HH, et al. Economic evaluation for mass vaccination against COVID-19. J Formos Med Assoc. 2021 Jun;120 Suppl 1:S95–S105. DOI: 10.1016/j.jfma.2021.05.020
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.jfma.2021.05.020&link_type=DOI) 

72. 72.Kohli M, Maschio M, Becker D, Weinstein MC. The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: Use of cost-effectiveness modeling to inform vaccination prioritization. Vaccine. 2021 Feb 12;39(7):1157–64. DOI: 10.1016/j.vaccine.2020.12.078
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.vaccine.2020.12.078&link_type=DOI) 

73. 73.Shaker M, Abrams EM, Greenhawt M. A Cost-Effectiveness Evaluation of Hospitalizations, Fatalities, and Economic Outcomes Associated with Universal Versus Anaphylaxis Risk-Stratified COVID-19 Vaccination Strategies. J Allergy Clin Immunol Pract. 2021 Jul;9(7):2658–68 e3. DOI: 10.1016/j.jaip.2021.02.054
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.jaip.2021.02.054&link_type=DOI) 

74. 74.Paltiel AD, Schwartz JL, Zheng A, Walensky RP. Clinical Outcomes Of A COVID-19 Vaccine: Implementation Over Efficacy. Health Aff (Millwood). 2021 Jan;40(1):42–52. DOI: 10.1377/hlthaff.2020.02054
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1377/hlthaff.2020.02054&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=33211536&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F05%2F05%2F2022.05.05.22274697.atom) 

75. 75.Wang B, Nolan R, Marshall H. COVID-19 Immunisation, Willingness to Be Vaccinated and Vaccination Strategies to Improve Vaccine Uptake in Australia. Vaccines. 2021;9(12):1467.